Jennison Associates LLC Sells 110,333 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS)

Jennison Associates LLC decreased its stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 21.2% during the third quarter, according to its most recent filing with the SEC. The institutional investor owned 410,057 shares of the company’s stock after selling 110,333 shares during the period. Jennison Associates LLC owned 1.43% of Krystal Biotech worth $74,643,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in KRYS. GAMMA Investing LLC increased its holdings in Krystal Biotech by 160.3% during the 2nd quarter. GAMMA Investing LLC now owns 151 shares of the company’s stock worth $28,000 after acquiring an additional 93 shares during the period. Jamison Private Wealth Management Inc. bought a new position in shares of Krystal Biotech in the second quarter worth $28,000. Key Financial Inc bought a new position in shares of Krystal Biotech in the second quarter worth $28,000. Blue Trust Inc. boosted its stake in Krystal Biotech by 2,328.6% during the second quarter. Blue Trust Inc. now owns 170 shares of the company’s stock valued at $30,000 after buying an additional 163 shares during the period. Finally, Values First Advisors Inc. bought a new stake in Krystal Biotech during the third quarter valued at $53,000. Institutional investors own 86.29% of the company’s stock.

Insiders Place Their Bets

In related news, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $197.76, for a total value of $4,944,000.00. Following the sale, the insider now directly owns 1,500,882 shares of the company’s stock, valued at $296,814,424.32. This trade represents a 1.64 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders own 14.10% of the company’s stock.

Krystal Biotech Stock Performance

Shares of KRYS opened at $178.10 on Thursday. Krystal Biotech, Inc. has a fifty-two week low of $99.00 and a fifty-two week high of $219.34. The firm has a market cap of $5.12 billion, a price-to-earnings ratio of 100.62 and a beta of 0.82. The firm has a 50 day moving average price of $180.45 and a 200-day moving average price of $182.02.

Krystal Biotech (NASDAQ:KRYS) last posted its quarterly earnings results on Monday, November 4th. The company reported $0.91 earnings per share for the quarter, topping the consensus estimate of $0.84 by $0.07. The business had revenue of $83.84 million during the quarter, compared to the consensus estimate of $82.94 million. Krystal Biotech had a net margin of 21.68% and a return on equity of 7.54%. The firm’s revenue for the quarter was up 879.9% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.67) earnings per share. As a group, equities research analysts predict that Krystal Biotech, Inc. will post 2.97 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on KRYS. William Blair raised Krystal Biotech to a “strong-buy” rating in a report on Friday, August 30th. Stifel Nicolaus raised their target price on shares of Krystal Biotech from $204.00 to $220.00 and gave the company a “buy” rating in a research note on Wednesday, September 11th. Cantor Fitzgerald reissued an “overweight” rating on shares of Krystal Biotech in a research note on Thursday, August 29th. HC Wainwright reissued a “buy” rating and issued a $221.00 price target on shares of Krystal Biotech in a report on Tuesday, November 5th. Finally, Evercore ISI lifted their price objective on shares of Krystal Biotech from $201.00 to $206.00 and gave the stock an “outperform” rating in a report on Monday, August 12th. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $202.29.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).